Iparomlimab and Tuvonralimab (QL1706) Clinical Trials
3 recruitingDrug
Phase 23
Showing 1–3 of 3 trials
Recruiting
Phase 2
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer
Uterine Cervical NeoplasmsLocally Advanced
Sun Yat-sen University103 enrolled1 locationNCT07646301
Recruiting
Phase 2
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
HER2-negativeLow PD-L1 ExpressingUnresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University77 enrolled29 locationsNCT06932068
Recruiting
Phase 2
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Gastroesophageal-junction CancerMetastatic Gastric CancerAdvanced Gastric Cancer+1 more
Beijing Friendship Hospital32 enrolled1 locationNCT07315854